MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced additional data from the 28-week Qnexa phase 2 study (OB-202) in type 2 diabetics. A subset analysis of subjects with higher cardiovascular risk factors at baseline had significantly greater improvements on Qnexa as compared to placebo. The analysis population is comprised of subjects with elevated baseline risk factors that were in the upper quartile of the overall study population.
